CAM
CLVS

Cormorant Asset Management’s Clovis Oncology, Inc. CLVS Stock Holding History

Cormorant Asset Management’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-650,000
Closed -$23.4M – 87
2016
Q3 		$23.4M Buy
+650,000
New +$13.9M 2.58% 11
2014
Q4 		– Sell
-70,000
Closed -$3.17M – 75
2014
Q3 		$3.17M Hold
70,000
– – 0.65% 42
2014
Q2 		$2.9M Sell
70,000
-50,000
-42% -$2.58M 0.77% 43
2014
Q1 		$8.31M Buy
120,000
+700
+0.6% +$51.4K 1.91% 22
2013
Q4 		$7.19M Buy
+119,300
New +$6.49M 2.09% 18

Other funds holding CLVS

PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Cormorant Asset Management's CLVS Position: Q4 2016 in Review

Cormorant Asset Management sold out of Clovis Oncology, Inc. (CLVS) in Q4 2016, closing a stake of 650,000 shares — an estimated $23.4M sold.

Cormorant Asset Management first reported a position in CLVS in Q4 2013 and held it in 5 quarters. The position peaked at $23.4M in Q3 2016. 167 funds tracked by Wall St. Rank hold CLVS as of Q4 2016.

  • Cormorant Asset Management reported no remaining Clovis Oncology, Inc. position as of Q4 2016 after selling out during the quarter.
  • Cormorant Asset Management sold 650,000 Clovis Oncology, Inc. shares in Q4 2016, an estimated $23.4M.
  • Cormorant Asset Management first reported a position in Clovis Oncology, Inc. in Q4 2013 and held it in 5 quarters.
  • Cormorant Asset Management's Clovis Oncology, Inc. position peaked at $23.4M in Q3 2016.
  • 167 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2016.

Based on Cormorant Asset Management's 13F filing for Q4 2016, filed 14 Feb 2017.